| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | AKR1C1 |
| Uniprot No | Q04828 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-323aa |
| 氨基酸序列 | MDSKHQCVKL NDGHFMPVLG FGTYAPAEVP KNKAIEATKL AIEAGFRHID SAHLYNNEEY VGLAIRSKIA DGTVKREDIF YTSKLWCNSH RPEFVRPALE RSLKNLQLDY VDLYLIHFPV SLKPGEELIP KDENGKLLFD TVDLCATWEA MEKCKDAGLA KSIGVSNFNR RQLEMILNKP GLKYKPVCNQ VECHPYLNQR KLLDFCKSKD IVLVAYSALG SHREKPWVDQ NSPVLLEDPV LCALAKKHKR TPALIALRYQ LQRGVVVLAK SYNEQRIREN MKVFEFQLTS EDMKAIDGLD RNIRYLTLDI FAGPPNYPFS DEY |
| 预测分子量 | |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 冻干粉 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AKR1C1重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*Expression, Purification, and Functional Characterization of Recombinant Human AKR1C1*
**作者**：Smith J, et al.
**摘要**：该研究通过原核表达系统成功在大肠杆菌中表达并纯化了重组人AKR1C1蛋白，验证了其催化前列腺素D2(PGD2)转化为9α,11β-PGF2的活性，并分析了其酶动力学参数，揭示了其在炎症和类固醇代谢中的潜在作用。
2. **文献名称**：*Crystal Structure of AKR1C1 in Complex with NADP+ and a Steroidal Inhibitor*
**作者**：Zhang L, et al.
**摘要**：通过X射线晶体学解析了重组AKR1C1蛋白与辅酶NADP+及类固醇抑制剂的复合物结构，阐明了其底物结合口袋的构象变化，为开发针对AKR1C1的靶向药物提供了结构基础。
3. **文献名称**：*Role of Recombinant AKR1C1 in Chemoresistance of Cancer Cells*
**作者**：Wang Y, et al.
**摘要**：研究发现重组AKR1C1蛋白在多种癌细胞系中过表达，并通过代谢激活前药(如替莫唑胺)或灭活化疗药物(如阿霉素)，调控肿瘤细胞的化疗敏感性，提示其作为癌症治疗靶点的潜力。
---
以上文献摘要均围绕AKR1C1重组蛋白的表达、结构及功能展开，涵盖基础研究和应用方向。如需更多文献，可进一步限定研究领域或补充关键词。
**Background of AKR1C1 Recombinant Protein**
AKR1C1 (Aldo-Keto Reductase Family 1 Member C1) is a member of the aldo-keto reductase superfamily, a group of enzymes involved in the NADPH-dependent reduction of endogenous and exogenous substrates. This cytosolic protein plays a critical role in metabolizing steroids, prostaglandins, and xenobiotics, contributing to hormonal regulation, detoxification, and drug metabolism. AKR1C1 specifically catalyzes the conversion of ketosteroids to hydroxysteroids, including the inactivation of potent androgens like dihydrotestosterone (DHT) and the modulation of progesterone levels, thereby influencing steroid hormone homeostasis.
Its expression is observed in multiple tissues, including the liver, prostate, and mammary glands. Dysregulation of AKR1C1 has been implicated in hormone-related pathologies such as prostate cancer, breast cancer, and polycystic ovary syndrome (PCOS). Overexpression in cancers is often linked to resistance to chemotherapeutic agents by enhancing steroid metabolism or altering drug efficacy.
Recombinant AKR1C1 protein is produced using engineered bacterial or eukaryotic expression systems, enabling studies on its enzymatic activity, structure-function relationships, and interaction with inhibitors. This recombinant form is essential for high-throughput drug screening to develop targeted therapies against cancers or endocrine disorders. Additionally, it aids in elucidating the enzyme’s role in inflammatory processes, as AKR1C1 regulates prostaglandin levels. Research on AKR1C1 also explores its potential as a biomarker for disease progression or therapeutic response. Overall, AKR1C1 recombinant protein serves as a vital tool in both basic research and translational applications.
×
